The Abu Dhabi delegation will participate in the visit which will kick-off in Washington DC with a visit the Children’s National Hospital…reports Asian Lite News
A high-profile Abu Dhabi health delegation will be visiting the United States of America this month to explore prospects of joint collaboration within the framework of healthcare at large and life science in specific.
The visit is expected to see meetings and groundbreaking agreement signings with leading partners to explore and activate collaborations in life science and real-world evidence, digital health, research and development, supply chain and many other areas.
The visit aims to lay down sustainable mechanisms that empower the healthcare sector in both countries as well as showcase Abu Dhabi’s distinguished healthcare ecosystem.
Headed by Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the delegation will witness the participation of seven key entities representing Abu Dhabi’s healthcare and life science ecosystem including the DoH, Abu Dhabi Investment Office (ADIO), Mubadala Health, G42, Abu Dhabi Ports, ADQ, Etihad Cargo and Pure Health.
The Abu Dhabi delegation will participate in the visit which will kick-off in Washington DC with a visit the Children’s National Hospital, home to the Sheikh Zayed Institute for Pediatric Surgical Innovation.
As part of the visit, the delegation will stop in Boston to visit various healthcare and biopharmaceutical facilities to explore potential collaborations with global partners.
The visit seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region as well as exchange knowledge and experiences across the sector.
The visit will conclude in San Diego where the Abu Dhabi delegation will participate in the BIO International Convention from June 13-16, 2022 to showcase the domestic growth and economic development of Abu Dhabi’s biotechnology industry.
Abu Dhabi is also home to renowned healthcare providers such as Cleveland Clinic, Imperial College London, Mayo Clinic and Moorefields Eye Hospital. Moreover, the emirate has been working closely with key players in the biopharmaceutical industry including Pfizer, AstraZeneca, Roche, Novartis, GSK, Sanofi, MSD and Johnson and Johnson among others to boost local and global capabilities related to research and innovation in life science, digital health and supply chain – strengthening its position as a leading destination in healthcare and life sciences.
Commenting on the Mission, Abdulla Al Hamed said: “More than ever today, the international community understands the importance of cross collaboration and unified efforts across all sectors. While we battled the Covid-19 pandemic, the world came to realise that the only way to overcome a global healthcare crisis is to band together. We witnessed the international community join forces and explore solutions for the health and wellbeing of all. The UAE and Abu Dhabi are strong proponents for unity and tolerance, core values which have been exemplified by our efforts to bolster the healthcare industry at large in recent years.”
ALSO READ:UAE GDP to grow at 5.4% in 2022
In a continuous bid to boost international collaboration across the healthcare sector, the Abu Dhabi delegation is set to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as provide quality care to patients.
Abu Dhabi continues to work in unison with global strategic partners to set the stage for a future driven by healthcare technology, innovation and artificial intelligence as part of its transformation strategy that aims to further enhance the quality of the healthcare sector’s outcomes.
